Top

Published in:

01-07-2009 | Review

Colitis-associated cancer: the role of T cells in tumor development

Authors: Maximilian J. Waldner, Markus F. Neurath

Published in: Seminars in Immunopathology | Issue 2/2009

Abstract

Chronic inflammation severely increases the risk for cancer development as seen in patients with inflammatory bowel disease (IBD). Although the exact mechanisms of inflammation-associated tumor development remain to be shown, a role for the adaptive immune system has been implicated in colitis-associated cancer (CAC). In fact, CD4+ effector T cells, which promote chronic inflammation in IBD, create a tumor convenient environment, which can lead to cancer initiation, promotion, and progression. Thereby, the cytokines interleukin-6 and tumor necrosis factor-α constitute an important link between inflammation and tumor growth. Furthermore, cytotoxic CD8+ T cells, which usually are protective as part of the host antitumor immune response in sporadic cancer, can contribute to the aggravation of chronic inflammation and thereby support tumor development. In contrast, regulatory T cells, which have been shown to attenuate tumor immunosurveillance, act as potent suppressors of chronic inflammation and thus can have protective effects in CAC. This review discusses the role of the adaptive immune response and especially T cells in the pathogenesis CAC and possible implications for the therapeutic applications.

Gyde S, Prior P, Dew MJ, Saunders V, Waterhouse JA, Allan RN (1982) Mortality in ulcerative colitis. Gastroenterology 83:36–43PubMed

Choi PM, Zelig MP (1994) Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35:950–954. doi:10.1136/gut.35.7.950 CrossRefPubMed

Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854–862. doi:10.1002/1097-0142(20010215) 91:4<854::AID-CNCR1073>3.0.CO;2-Z CrossRefPubMed

Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526–535. doi:10.1136/gut.48.4.526 CrossRefPubMed

Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627–1640. doi:10.1016/S0140-6736(07)60750-8 CrossRefPubMed

Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427–434. doi:10.1038/nature06005 CrossRefPubMed

Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417–429. doi:10.1056/NEJMra020831 CrossRefPubMed

Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA et al (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157:1261–1270PubMed

Neurath MF (2007) IL-23: a master regulator in Crohn disease. Nat Med 13:26–28. doi:10.1038/nm0107-26 CrossRefPubMed

10.

Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433–439. doi:10.1016/j.semcancer.2004.06.006 CrossRefPubMed

11.

Kundu JK, Surh YJ (2008) Inflammation: gearing the journey to cancer. Mutat Res 659:15–30. doi:10.1016/j.mrrev.2008.03.002 CrossRefPubMed

12.

Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R (2008) Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract 204:511–524. doi:10.1016/j.prp.2008.04.011 CrossRefPubMed

13.

Wong M, Ziring D, Korin Y, Desai S, Kim SJ, Lin J et al (2008) TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 126:121–136. doi:10.1016/j.clim.2007.08.013 CrossRefPubMed

14.

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244–279. doi:10.1016/j.pharmthera.2007.10.001 CrossRefPubMed

15.

Rutgeerts P, Vermeire S, Van Assche G (2009) Biological therapies for inflammatory bowel diseases. Gastroenterology 136:1182–1197. doi:10.1053/j.gastro.2009.02.001 CrossRefPubMed

16.

Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S et al (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:560–570. doi:10.1172/JCI32453 PubMed

17.

Neurath MF, Pettersson S, Meyer Zum Büschenfelde KH, Strober W (1996) Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2:998–1004. doi:10.1038/nm0996-998 CrossRefPubMed

18.

Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296. doi:10.1016/j.cell.2004.07.013 CrossRefPubMed

19.

Atreya I, Atreya R, Neurath MF (2008) NF-kappaB in inflammatory bowel disease. J Intern Med 263:591–596. doi:10.1111/j.1365-2796.2008.01953.x CrossRefPubMed

20.

Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A et al (1991) Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 50:104–111. doi:10.1159/000200747 CrossRefPubMed

21.

Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A et al (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126:989–996. doi:10.1053/j.gastro.2004.01.012 discussion 947CrossRefPubMed

22.

Yamamoto M, Yoshizaki K, Kishimoto T, Ito H (2000) IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164:4878–4882PubMed

23.

Rose-John S, Scheller J, Elson G, Jones SA (2006) Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80:227–236. doi:10.1189/jlb.1105674 CrossRefPubMed

24.

Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2:619–626. doi:10.1038/ncprheum0338 CrossRefPubMed

25.

Van Snick J (1990) Interleukin-6: an overview. Annu Rev Immunol 8:253–278. doi:10.1146/annurev.iy.08.040190.001345 CrossRefPubMed

26.

Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20. doi:10.1042/BJ20030407 CrossRefPubMed

27.

Chung YC, Chang YF (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222–226. doi:10.1002/jso.10269 CrossRefPubMed

28.

Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L et al (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169–178. doi:10.1006/clim.2001.5163 CrossRefPubMed

29.

Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A et al (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491–501. doi:10.1016/j.immuni.2004.07.020 CrossRefPubMed

30.

Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15:91–102. doi:10.1016/j.ccr.2009.01.002 CrossRefPubMed

31.

Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al (2009) IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103–113. doi:10.1016/j.ccr.2009.01.001 CrossRefPubMed

32.

Yu P, Fu YX (2006) Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86:231–245. doi:10.1038/labinvest.3700389 CrossRefPubMed

33.

Osawa E, Nakajima A, Fujisawa T, Kawamura YI, Toyama-Sorimachi N, Nakagama H et al (2006) Predominant T helper type 2-inflammatory responses promote murine colon cancers. Int J Cancer 118:2232–2236. doi:10.1002/ijc.21639 CrossRefPubMed

34.

Strasly M, Cavallo F, Geuna M, Mitola S, Colombo MP, Forni G et al (2001) IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 166:3890–3899PubMed

35.

Verbik DJ, Stinson WW, Brunda MJ, Kessinger A, Joshi SS (1996) In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin Exp Metastasis 14:219–229PubMed

36.

Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M et al (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223–1230. doi:10.1084/jem.178.4.1223 CrossRefPubMed

37.

Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ et al (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153:1697–1706PubMed

38.

Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G et al (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677–4685. doi:10.1158/1078-0432.CCR-07-0776 CrossRefPubMed

39.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998. doi:10.1038/ni1102-991 CrossRefPubMed

40.

Shibata M, Nezu T, Kanou H, Abe H, Takekawa M, Fukuzawa M (2002) Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 34:416–420. doi:10.1097/00004836-200204000-00006 CrossRefPubMed

41.

Kettunen HL, Kettunen AS, Rautonen NE (2003) Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res 63:5136–5142PubMed

42.

Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666. doi:10.1056/NEJMoa051424 CrossRefPubMed

43.

Endo Y, Marusawa H, Kou T, Nakase H, Fujii S, Fujimori T et al (2008) Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 135:889–898. doi:10.1053/j.gastro.2008.06.091 898.e881-883CrossRefPubMed

44.

Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF (1973) Crohn's disease and cancer. N Engl J Med 289:1099–1103PubMed

45.

Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JA, Allan RN (1980) Malignancy in Crohn's disease. Gut 21:1024–1029. doi:10.1136/gut.21.12.1024 CrossRefPubMed

46.

Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN (1994) Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35:1590–1592. doi:10.1136/gut.35.11.1590 CrossRefPubMed

47.

Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146. doi:10.1038/nri1001 CrossRefPubMed

48.

Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F et al (1997) Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112:1169–1178. doi:10.1016/S0016-5085(97)70128-8 CrossRefPubMed

49.

Stuber E, Strober W, Neurath M (1996) Blocking the CD40L–CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med 183:693–698. doi:10.1084/jem.183.2.693 CrossRefPubMed

50.

Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281–1290. doi:10.1084/jem.182.5.1281 CrossRefPubMed

51.

Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D et al (2004) Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351:2069–2079. doi:10.1056/NEJMoa033402 CrossRefPubMed

52.

Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715–725. doi:10.1016/S1074-7613(00)00070-4 CrossRefPubMed

53.

Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB et al (2007) Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132:2359–2370. doi:10.1053/j.gastro.2007.03.104 CrossRefPubMed

54.

Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461–1463. doi:10.1126/science.1135245 CrossRefPubMed

55.

Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240. doi:10.1084/jem.20041257 CrossRefPubMed

56.

Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M (2008) Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 226:87–102. doi:10.1111/j.1600-065X.2008.00712.x CrossRefPubMed

57.

Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S (1998) Interleukin-17. Int Rev Immunol 16:541–551. doi:10.3109/08830189809043008 CrossRefPubMed

58.

Korn T, Oukka M, Kuchroo V, Bettelli E (2007) Th17 cells: effector T cells with inflammatory properties. Semin Immunol 19:362–371. doi:10.1016/j.smim.2007.10.007 CrossRefPubMed

59.

Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B et al (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116:1310–1316. doi:10.1172/JCI21404 CrossRefPubMed

60.

Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C et al (2008) RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology . doi:10.1053/j.gastro.2008.10.018 PubMed

61.

Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C et al (2008) Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 14:437–445. doi:10.1002/ibd.20339 CrossRefPubMed

62.

Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K et al (2006) IL-23 promotes tumour incidence and growth. Nature 442:461–465. doi:10.1038/nature04808 CrossRefPubMed

63.

Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T et al (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101:2620–2627. doi:10.1182/blood-2002-05-1461 CrossRefPubMed

64.

Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P (2000) Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 12:1092–1099. doi:10.1006/cyto.2000.0681 CrossRefPubMed

65.

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148. doi:10.1016/j.immuni.2004.07.017 CrossRefPubMed

66.

Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26:373–400. doi:10.1007/s10555-007-9072-0 CrossRefPubMed

67.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491–3494PubMed

68.

Atreya I, Schimanski CC, Becker C, Wirtz S, Dornhoff H, Schnürer E et al (2007) The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. Gut 56:1572–1578. doi:10.1136/gut.2006.117812 CrossRefPubMed

69.

Smith CL, Dulphy N, Salio M, Cerundolo V (2002) Immunotherapy of colorectal cancer. Br Med Bull 64:181–200. doi:10.1093/bmb/64.1.181 CrossRefPubMed

70.

Bergmann-Leitner ES, Duncan EH, Leitner WW (2003) Identification and targeting of tumor escape mechanisms: a new hope for cancer therapy? Curr Pharm Des 9:2009–2023. doi:10.2174/1381612033454199 CrossRefPubMed

71.

Michael-Robinson JM, Pandeya N, Walsh MD, Biemer-Huttmann AE, Eri RD, Buttenshaw RL et al (2006) Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer. J Pathol 208:381–387. doi:10.1002/path.1895 CrossRefPubMed

72.

Müller S, Lory J, Corazza N, Griffiths GM, Z'graggen K, Mazzucchelli L et al (1998) Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. Am J Pathol 152:261–268PubMed

73.

Souza HS, Tortori CJ, Castelo-Branco MT, Carvalho AT, Margallo VS, Delgado CF et al (2005) Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways. Int J Colorectal Dis 20:277–286. doi:10.1007/s00384-004-0639-8 CrossRefPubMed

74.

Okazaki K, Morita M, Nishimori I, Sano S, Toyonaga M, Nakazawa Y et al (1993) Major histocompatibility antigen-restricted cytotoxicity in inflammatory bowel disease. Gastroenterology 104:384–391PubMed

75.

Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L et al (2006) Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 116:1713–1722. doi:10.1172/JCI25112 CrossRefPubMed

76.

Ziegler SF (2006) FOXP3: of mice and men. Annu Rev Immunol 24:209–226. doi:10.1146/annurev.immunol.24.021605.090547 CrossRefPubMed

77.

Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL (1993) Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 5:1461–1471. doi:10.1093/intimm/5.11.1461 CrossRefPubMed

78.

Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL (1994) Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1:553–562. doi:10.1016/1074-7613(94)90045-0 CrossRefPubMed

79.

Read S, Malmström V, Powrie F (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+) CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192:295–302. doi:10.1084/jem.192.2.295 CrossRefPubMed

80.

Huibregtse IL, van Lent AU, van Deventer SJ (2007) Immunopathogenesis of IBD: insufficient suppressor function in the gut? Gut 56:584–592. doi:10.1136/gut.2006.103523 CrossRefPubMed

81.

Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263–274. doi:10.1016/0092-8674(93)80068-P CrossRefPubMed

82.

Berg DJ, Davidson N, Kühn R, Müller W, Menon S, Holland G et al (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98:1010–1020. doi:10.1172/JCI118861 CrossRefPubMed

83.

Poutahidis T, Haigis KM, Rao VP, Nambiar PR, Taylor CL, Ge Z et al (2007) Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. Carcinogenesis 28:2614–2623. doi:10.1093/carcin/bgm180 CrossRefPubMed

84.

Becker C, Fantini MC, Neurath MF (2006) TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev 17:97–106. doi:10.1016/j.cytogfr.2005.09.004 CrossRefPubMed

85.

Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E et al (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11:8326–8331. doi:10.1158/1078-0432.CCR-05-1244 CrossRefPubMed

86.

Ishibashi Y, Tanaka S, Tajima K, Yoshida T, Kuwano H (2006) Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep 15:1315–1319PubMed

87.

Erdman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, Fox JG et al (2005) CD4+ CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65:3998–4004. doi:10.1158/0008-5472.CAN-04-3104 CrossRefPubMed

Title: Colitis-associated cancer: the role of T cells in tumor development
Authors: Maximilian J. Waldner
Markus F. Neurath
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 2/2009
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-009-0161-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Extra-adrenal glucocorticoid synthesis in the intestinal epithelium: more than a drop in the ocean?

Induction of intestinal lymphoid tissue formation by intrinsic and extrinsic signals

Living on the edge: immune cells and immunopathology in the intestinal mucosa

Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection

Intestinal macrophages: differentiation and involvement in intestinal immunopathologies

Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials